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Abstract
Vaccination with the pre-erythrocytic malaria vaccine RTS,S induces high levels of antibodies and CD4+ T cells specific for
the circumsporozoite protein (CSP). Using a biologically-motivated mathematical model of sporozoite infection fitted to
data from malaria-naive adults vaccinated with RTS,S and subjected to experimental P. falciparum challenge, we
characterised the relationship between antibodies, CD4+ T cell responses and protection from infection. Both anti-CSP
antibody titres and CSP-specific CD4+ T cells were identified as immunological surrogates of protection, with RTS,S induced
anti-CSP antibodies estimated to prevent 32% (95% confidence interval (CI) 24%–41%) of infections. The addition of RTS,S-
induced CSP-specific CD4+ T cells was estimated to increase vaccine efficacy against infection to 40% (95% CI, 34%–48%).
This protective efficacy is estimated to result from a 96.1% (95% CI, 93.4%–97.8%) reduction in the liver-to-blood parasite
inoculum, indicating that in volunteers who developed P. falciparum infection, a small number of parasites (often the
progeny of a single surviving sporozoite) are responsible for breakthrough blood-stage infections.
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Introduction
Malaria continues to pose a serious public health challenge, with
an estimated 655,000 malaria associated deaths every year [1],
despite the large scale roll out of insecticide treated nets across the
globe [2] and the switch to treatment with highly efficacious
artemisinin combination therapies [3]. An efficacious malaria
vaccine would be an invaluable addition to the range of currently
available malaria control interventions. The malaria vaccine
candidate RTS,S, targeting the pre-erythrocytic stages of Plasmo-
dium falciparum, has been shown to prevent malaria infection and
clinical disease in Phase 2b field trials in infants [4–6], children
[7,8] and adults [9,10] as well as more recently in a large Phase 3
trial underway in Africa [11]. RTS,S targets the circumsporozoite
protein (CSP) and has been formulated with either of two different
adjuvant systems; AS02 or AS01. In field trials where RTS,S/
AS01 and RTS,S/AS02 have been directly compared, RTS,S/
AS01 has been found to be more immunogenic [9,12,13].
Sporozoites inoculated into the skin via mosquito bite can be
opsonised and immobilised by vaccine-induced anti-CSP antibod-
ies as they migrate through tissue [14]. Sporozoites that reach the
liver will invade hepatocytes where they undergo hepatic
development. Hepatocyte invasion could potentially be prevented
by anti-CSP antibodies [15]. Intracellular Plasmodium parasites can
be targeted by vaccine-induced CSP-specific CD4+ T cells leading
to killing of the infected hepatocyte [16,17]. After approximately
6.5 days of hepatic development [18,19], merozoites will be
released into the blood circulation to begin the erythrocytic stage
of infection. When released from the liver, merozoites undergo
blood-stage replication causing an exponential increase in parasite
numbers. Studies of early blood-stage P. falciparum infection in
human volunteers have demonstrated that the smaller the liver-to
blood inoculum, the longer the time taken for parasite density to
reach a given threshold [20,21].
Vaccination with RTS,S induces anti-CSP antibodies and CSP-
specific CD4+ T cells that produce a mixture of cytokines (such as
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IL-2, TNF-a, IFN-c) and may also express the co-stimulatory
molecule CD40L [17,22]. Protection from infection and clinical
disease has been shown to be associated with both naturally-
acquired and RTS,S induced anti-CSP antibodies [23,24]. CSP-
specific CD4+ T cells have been associated with protection from
infection in RTS,S vaccinated children [25] and in children with
naturally-acquired immunity [26]. Characterising precise immu-
nological surrogates of protection in field trials is, however,
complicated by heterogeneous exposure to malaria, temporal
changes in immune markers, and interactions with naturally-
acquired immunity [27,28]. In contrast, challenge trials in
malaria-naı¨ve adults provide an ideal opportunity to investigate
the dose-response relationship between immune markers and
protection from infection as the infectious dose can be controlled
and the timing known, there is no naturally-acquired immunity,
and immune markers can be measured on the day of challenge.
Kester et al [29] undertook such a challenge study for RTS,S/
AS01 and RTS,S/AS02 in malaria naı¨ve adults. 52 volunteers
were vaccinated with RTS,S/AS01 and 50 volunteers with
RTS,S/AS02. 36 volunteers were recruited as controls and hence
remained unvaccinated. 104 volunteers were challenged with the
bites of five P. falciparum infectious Anopheles stephensi mosquitoes
[30]. The efficacy of RTS,S/AS01 and RTS,S/AS02 against
infection was estimated to be 50% (95% CI, 32.9%–67.1%) and
32% (95% CI, 17.6%–47.6%), respectively. Protected vaccine
recipients had higher anti-CSP antibody titres (mean, 188 vs.
73 mg/mL; P,0.001), and higher numbers of CSP-specific CD4+
T cells per million CD4+ T cells (median, 963 vs. 308 CSP-specific
CD4+ T cells; P,0.001) than unprotected vaccine recipients. The
study also demonstrated significantly higher levels of anti-CSP
antibody titres and numbers of CSP-specific CD4+ T cells in those
vaccinated with RTS,S/AS01 compared to RTS,S/AS02. Here
we re-analyze the data to investigate in detail the association
between RTS,S-induced anti-CSP antibodies, CD4+ T cells and
protection from infection using a biologically-motivated mathe-
matical model of P. falciparum sprorozoite inoculation to estimate
the probability of infection and the delay in onset of parasitemia
due to vaccination. Our results provide insights into the likely
mechanism of action of the RTS,S vaccine as well as providing a
more generalised framework for assessing the efficacy of vaccines
in early stage development.
Methods
Challenge Trial
Kester et al [29] evaluated the efficacy and safety of the RTS,S
malaria vaccine when formulated with the AS01 and AS02
adjuvant systems in 104 malaria naı¨ve adults challenged with the
bites of five mosquitoes infectious with the homologous 3D7 strain
of P. falciparum. 36 volunteers receiving RTS,S/AS01 vaccination
were challenged, and 17 were completely protected from infection.
9 of those that were completely protected from infection were re-
challenged 5 months later. 44 of the volunteers receiving RTS,S/
AS02 vaccination were challenged, and 14 were completely
protected from infection. 9 of those that were completely protected
were re-challenged 5 months later. 24 of the controls were
challenged at the first round; the remaining 12 were challenged 5
months later. On 85 of the occasions when vaccinated volunteers
were challenged, measurements of vaccine-induced immune
responses were available. Following challenge, volunteers were
assessed by blood smears taken twice daily starting on day 6.5 until
day 14 and then once daily until the end of the study period at day
21. Volunteers who tested positive for malaria parasites at any
point in the study were then treated with chloroquine, irrespective
of symptoms.
Anti-CSP antibodies were measured by evaluating IgG
responses to the P. falciparum CSP-repeat region measured using
enzyme-linked immunospot assay (ELISA). Measurements of
antibody titre were analysed in units of mg/mL. In Phase II and
Phase III field trials of RTS,S, antibody titres have been reported
in ELISA units (EU/mL). The number of CD4+ or CD8+ T cells
responding to CSP antigen and expressing the immune markers
CD40L, IFN-c, IL-2 and TNF-a per million CD4+ or CD8+ T
cells were also measured (see Kester [Kester] for further details).
RTS,S induced CD8+ T cell responses were minimal and were not
associated with protection from infection. The measure of cell-
mediated immunity (CMI) used in this analysis is the number of
CD4+ T cells expressing $2 immune markers per million CD4+ T
cells. Data on time to onset of parasitemia and antibody and
cellular responses from control and vaccinated volunteers at both
challenge and re-challenge were analyzed. Correlations between
immune responses and comparisons between protected and
infected volunteers are presented in the Supplementary Informa-
tion in (Table S5 in File S1).
Table 1. Parameters describing the biology of P. falciparum infection.
Parameter Description Value Reference
n mean number of successful sporozoites per challenge 150 (75–237) estimated
sn standard deviation of number of sporozoites 194 (93–324) estimated
tL duration of liver-stage development 6.5 days Murphy et al [18]
m mean number of merozoites released per sporozoite 2,136 (1,834–3,606) estimated
sm standard deviation in number of merozoites per sporozoite 4,460 (3,394–7,613) estimated
m daily blood-stage parasite multiplication rate 3.8 day
21 Bejon et al [20]
PT threshold number of parasites for detection of infection 50,000,000 parasites Bejon et al [41]
bab anti-CSP titre for 50% reduction in sporozoite survival probability 6.62 (1.34–16.29) mg/mL estimated
aab shape parameter for antibody dose-response 1.32 (0.85–1.77) estimated
bCMI number of CD4
+ T cells for 50% reduction in sporozoite survival probability 1,367 (795–4,662) cells/
million
estimated
Estimated parameters are shown with 95% confidence intervals.
doi:10.1371/journal.pone.0061395.t001
RTS,S Vaccine-Induced Responses and Infection
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Figure 1. Time to onset of parasitemia. Estimated time to onset of parasitemia for those individuals that are infected as a function of anti-CSP
antibody titre (A) when combined with T cells expressing two or more of TNF-a, IL-2, IFN-c or CD40L (B), TNF-a+ CD4+ T cells (C), IL-2+ CD4+ T cells (D),
IFN-c+ CD4+ T cells (E), or CD40L+ CD4+ T cells (F). The best estimate is given by the black line and the 95% confidence intervals are shown in grey. The
times to onset of parasitemia in the infectivity controls, who didn’t have detectable anti-CSP antibody titres or CSP-specific T cells are clustered on the
left at (0, 8–12) (yellow points). The anti-CSP antibody titres or CSP-specific T cells of protected volunteers in whom there was no onset of parasitemia,
are shown at the top for comparison (blue points). The model accurately replicates the association between time to onset of parasitemia in those that
become infected (shown in gold and red) and anti-CSP antibodies (B), but does not do so for markers of cellular immunity (B–F), suggesting that the
delay in parasitemia due to killing of sporozoites is best explained by anti-CSP antibody titres.
doi:10.1371/journal.pone.0061395.g001
Table 2. Comparison of models where protection from infection and time to onset of parasitemia depend on (i) anti-CSP
antibodies and CSP-specific CD4+ T cells; (ii) anti-CSP antibodies only; (iii) CSP-specific CD4+ T cells only; and (iv) vaccination status
only.
Parameter estimates
Model n sn m sm VEs bab aab bCMI DAIC
antibodies & CD4+ T cells 150 194 2136 4460 – 6.62 1.32 1367 0
antibodies only 156 210 2056 4205 – 5.83 1.38 – 4.34
vaccine status only 74 96 4463 9340 0.97 – – – 29.30
CD4+ T cells only 202 447 658 1444 – – – 489 76.62
Parameters are as defined in Table 1 and VEs is the probability that a sporozoite is killed for the vaccination status only model. The ranking of models by AIC highlights
the finding that the data are best explained by a model that includes both anti-CSP antibody titres and numbers of CD4+ T cells, and that a model with anti-CSP
antibody titres only fits better than one with CD4+ T cells only.
doi:10.1371/journal.pone.0061395.t002
RTS,S Vaccine-Induced Responses and Infection
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Sporozoite Infection Model
Data from mosquito feeding studies indicates that the number of
inoculated sporozoites is highly variable [31–33], and hence we
assume the number of sporozoites inoculated during each
infectious challenge follows a Negative Binomial distribution with
probability mass function S(n, sn ) where the mean (n) and
standard deviation (sn) are parameters to be estimated and Sk is
used to denote the probability that k sporozoites initiate blood-
stage infection. Each sporozoite that survives liver stage develop-
ment is assumed to initiate blood-stage infection by releasing m
merozoites into the blood stream tL = 6.5 days after challenge [18].
We assume the number of merozoites released per sporozoite
follows a Gamma distribution with mean (m) and standard
deviation (sm) estimated during model fitting. Once in the blood,
parasites begin replication increasing in number by a fixed factor
m per day [20] (Table 1) until parasite numbers reach levels pT
sufficient for detection by slide microscopy [34]. Thus the duration
of time between emergence of merozoites from the liver and
detection (the delay in onset of parasitemia) can be used to
estimate the reduction in merozoites emerging from the liver, with
greater delays corresponding to greater reductions. Specifically, if
Q denotes the number of merozoites that initiate blood-stage
infection then an estimate can be obtained from the time T of
detection as Q~pTm
{(T{tL)
.
To prevent malaria infection, we assume that all sporozoites
must be killed, either by chance, by innate immune responses, or
by vaccine-induced immune responses. Prevention of infection or
reduction in parasite load in vaccinated volunteers following P.
falciparum challenge is assumed to depend on anti-CSP antibody
titres and the number of CSP-specific CD4+ T cells as well as other
factors which are captured as inter-individual variation. Paramet-
ric dose-response curves (a method commonly used in the
pharmacological literature [35]) are used to relate the anti-CSP
titres and/or number of CSP-specific CD4+ T cells to the observed
probability of a volunteer being protected following P. falciparum
challenge. Exponential and Hill-functions were considered for the
parametric dose response curves. For an exponential dose-
response, the probability of a sporozoite surviving an immune
response of magnitude x is f (x)~e
{ log (2)
x
b: For a Hill-function
dose-response the probability is f (x)~
1
1z
x
b
 a. Several markers
of vaccine-induced cellular responses were available and consid-
ered alone and in combination: CSP-specific T cells expressing
TNF-a, IL-2, IFN-c or CD40L.
Figure 2. Efficacy against infection as a function of anti-CSP antibody titre and CSP-specific CD4+ T cells. Estimated efficacy against
infection as a function of anti-CSP antibody titre and numbers of CSP-specific CD4+ T cells per million obtained from the sporozoite model. The
vertical dashed grey lines denote the median and 90% ranges of the observed anti-CSP antibody titres, and the horizontal dashed grey lines denote
the median and 90% ranges of observed numbers of CSP-specific CD4+ T cells. The solid black lines denote the isoclines for 30%, 50%, 70%, and 90%
vaccine efficacy against infection. The blue and brown points denote the anti-CSP antibody titres and numbers of CSP-specific CD4+ T cells of
protected and infected volunteers, respectively.
doi:10.1371/journal.pone.0061395.g002
RTS,S Vaccine-Induced Responses and Infection
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61395
Model Fitting
The model was fitted to patient data from both the vaccine and
control cohorts using maximum likelihood methods. Let
f (x)denote the probability that a single sporozoite will release
merozoites from the liver given antibody levels xab and T cell
number xcmi, then the probability that k sporozoites from an
infectious bite will release merozoites is given by
Sk xð Þ~ kzr{1
k
 
rr nf (x)ð Þk
nf (x)zrð Þrzk
where r~
n2
s2n{n
is a shape
parameter of the Negative Binomial distribution. If H denotes the
vector of parameters to be estimated and I indicates those
protected (I = 0) or infected (I = 1) then the data likelihood given
infection status I, merozoites emerging from the liver Q, and
immune response x is:
Table 3. Comparison of predicted (black) and observed (blue) efficacy against infection for the sporozoite infection model.
anti-CSP antibody titre (mg/mL)
2.7–78 78–183 183–1136 0–1136
CSP-specific CD4+ T
cells
1–268 12.6% 31.8% 47.6% 23.1%
12.5% (2/16) 37.5% (3/8) 25% (1/4) 21.4% (6/28)
268–820 12.6% 37.0% 57.3% 43.2%
33.3% (2/6) 14.3% (1/7) 62.5% (10/16) 44.8% (13/29)
820–8798 25.7% 51.9% 79.1% 54.1%
16.7% (1/6) 64.3% (9/14) 75.0% (6/8) 57.1% (16/28)
1–8798 15.4% 42.8% 62.1% 40.2%
17.9% (5/28) 44.8% (13/29) 60.7% (17/28) 41.2% (35/85)
Volunteers have been stratified into low, medium and high groups according to their anti-CSP antibody titre and number of CSP-specific T cells per million.
doi:10.1371/journal.pone.0061395.t003
Figure 3. Comparison of efficacy against infection and efficacy per sporozoite. Estimated efficacy against infection (green) and efficacy per
sporozoite (blue) with 95% confidence intervals as a function of anti-CSP antibody titres obtained using the sporozoite model. A histogram of the
distribution of anti-CSP antibody titres is shown in grey.
doi:10.1371/journal.pone.0061395.g003
RTS,S Vaccine-Induced Responses and Infection
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where j~f1,:::,Jg indexes the number of individuals in the study
and k indexes the number of sporozoites injected.
The likelihood can be interpreted as follows: if volunteer j with
immune marker xj is protected (Ij~0) then k = 0 sporozoites will
be successful with probability S0(xj). If volunteer j becomes
infected Ij~1, then infection will have been initiated by k[½1,?)
sporozoites with probability Sk(xj). Each of the ksuccessful
sporozoites will release a number of merozoites into the
bloodstream following a Gamma distribution C
m2
s2m
,
s2m
m
 !
. Model
fits were compared using the Akaike Information Criteria (AIC).
The association between anti-CSP antibodies, CSP-specific CD4+
T cells and protection from infection estimated by the sporozoite
infection model was further validated by fitting a binary infection
model where the presence or absence of infection following
challenge is the only outcome of interest, and time to onset of
parasitemia is ignored. Further mathematical details and likeli-
hoods for statistical fitting, as well as simpler regression models, are
given in the Supplementary Information (File S1).
Vaccine Efficacy
Our results can be summarised in terms of two different
representations of efficacy. We define efficacy against infection to
be the reduction in the probability of infection following challenge
from five P. falciparum infectious mosquitoes in vaccinated
volunteers compared to control volunteers. We additionally
calculate efficacy per sporozoite, defined to be the proportionate
reduction in the number of sporozoites initiating blood stage
infection (the liver-to-blood inoculum) [36].
Comparative Role of the Adjuvants
To investigate the hypothesis that the higher efficacy of RTS,S/
AS01 can be explained by its superior immunogenicity over
RTS,S/AS02, separate dose-response curves were fitted for anti-
CSP antibodies induced by RTS,S/AS01 or RTS,S/AS02.
Results
Sporozoite Infection Model
Figure 1 shows the estimated time to onset of parasitemia for a
model in which sporozoite survival is dependent on anti-CSP
antibody titres (A), and one of the following markers of cellular
immunity: CSP-specific T cells expressing two or more of TNF-a,
IL-2, IFN-c or CD40L (B);, TNF-a+ CD4+ T cells (C);, IL-2+
CD4+ T cells (D);, IFN-c+ CD4+ T cells (E);, and CD40L+ CD4+
T cells (F). The variation in the time to onset of parasitemia due to
variation in the number of sporozoites is captured in the width of
the confidence intervals. The model accurately replicates the
association between time to onset of parasitemia and anti-CSP
antibodies (Figure 1A), but not for markers of cellular immunity
(Figure 1B–F) suggesting that the delay in parasitemia due to
killing of sporozoites is predominantly attributable to antibody-
mediated responses. The combination of immune markers giving
Figure 4. Distribution of efficacy against infection. Estimated distribution of efficacy against infection induced by both RTS,S/AS02 and RTS,S/
AS01.
doi:10.1371/journal.pone.0061395.g004
RTS,S Vaccine-Induced Responses and Infection
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the best statistical fit to the data was anti-CSP antibodies and CSP-
specific CD4+ T cells producing two or more activation markers
(see Supplementary Information, Tables S1 and S2 in File S1).
Two functional forms for the shape of the relationship between
anti-CSP antibody titres or numbers of CSP-specific CD4+ T cells
and the probability that a single sporozoite survives intra-
hepatocytic development (dose-response curves) were tested.
Models with interaction between the antibody- and cell-mediated
responses were also tested (see Supplementary Information, Table
S1 in File S1), but didn’t result in a better statistical fit to the data
indicating no evidence that antibodies and cellular responses
confer protection synergistically. The model providing the best fit
to the data assumes that the probability of sporozoite survival
decreases with increasing anti-CSP antibody titres according to a
Hill function dose-response, and with increasing numbers of CSP-
specific CD4+ T cells according to an exponential dose-response
curve. The best fit parameters are shown in Table 1. We estimated
the mean number of sporozoites that successfully completed intra-
hepatocytic development to be 150 (95% CI 75–237) with
standard deviation 194 (95% CI 93–324). We estimate that the
number of merozoites released per sporozoite follows a Gamma
distribution with mean 2,136 (95% CI 1,834–3,606) and standard
deviation 4,460 (95% CI 3,394–7,614). The estimates of the mean
and variance of the numbers of sporozoites and merozoites are
dependent on the fixed parameter values in Table 1 for the
duration of liver-stage development and the daily blood-stage
multiplication rate (sensitivity analysis provided in Supplementary
Information, Table S9 in File S1).
The model assumption that sporozoite survival is dependent on
markers of antibody- and cell-mediated immunity was validated by
fitting a series of nested models where these assumptions were
adjusted. Table 2 shows the outcome of model fits where
sporozoite survival depends on (i) anti-CSP antibody titre and
numbers of CSP-specific CD4+ T cells; (ii) anti-CSP antibodies
only; (iii) CSP-specific CD4+ T cells only; and (iv) vaccination
status only. The large differences in the Akaike Information
Criteria (AIC, a measure of model goodness-of-fit) between models
indicates that there is statistical evidence that a model including
both antibody and cell-mediated immune responses provides a
better fit to the data than models with either alone, and that a
model with antibodies alone provides a better fit to the data than a
model with CSP-specific CD4+ T cells alone.
Vaccine Efficacy Against Infection
Table 3 compares the observed and model predicted efficacy
against infection (defined as the prevention of blood-stage infection
i.e. all sporozoites prevented from surviving intra-hepatocytic
development following five bites) for the volunteers stratified into
three equally sized groups by anti-CSP antibody titre and number
of CSP-specific CD4+ T cells. Efficacy against infection in
volunteers with the highest category of anti-CSP antibody titres
and of CSP-specific CD4+ T cells is estimated to be 79% (95% CI,
58%–89%). Efficacy against infection predicted by our model as a
continuous function of anti-CSP antibody titres and CSP-specific
CD4+ T cells is shown in Figure 2. In the absence of cellular
responses, vaccine-induced anti-CSP antibodies are estimated to
provide 32% (95% CI, 24%–41%) protection from infection.
Including the effect of the additional sporozoites killed by the CSP-
specific cellular response brings the model predicted efficacy
against infection to 40% (95% CI, 34%–48%). The existence of a
highly protected subgroup of volunteers suggests that efficacy
against infection in excess of 70% is possible if both anti-CSP
antibody titres and numbers of CSP-specific CD4+ T cells can be
boosted to high enough levels.
Vaccine Efficacy Per Sporozoite
We estimate the vaccine efficacy per sporozoite (defined as the
percentage reduction in the number of sporozoites initiating blood
stage infection – the proportion of parasites killed as opposed to
the proportion of infections prevented) to be 96.1% (95% CI,
93.5%–97.8%) suggesting that a very small number of parasites
are responsible for breakthrough infection. The striking discrep-
ancy between the proportion of parasites blocked and the
proportion of infections prevented is a consequence of the large
number of inoculated sporozoites and the potential for a single
sporozoite to initiate blood-stage infection. For volunteers
vaccinated with RTS,S/AS02, we estimate efficacy per sporozoite
to be 95.3% (95% CI, 92.3%–97.3%), and for those vaccinated
with RTS,S/AS01 to be 97.2% (95% CI, 95.0%–98.4%). Both
efficacy against infection and efficacy per sporozoite increase with
increasing anti-CSP titres and numbers of CSP-specific CD4+ T
cells (Figure 3). These estimates assume that sporozoites act
independently and may be lower if this assumption does not hold.
Effect of Adjuvant Formulation on Vaccine Efficacy
Vaccination is predicted to prevent infection in 40% (95% CI,
34%–48%) of challenges. For volunteers vaccinated with RTS,S/
AS02, we estimate efficacy against infection to be 34% (95% CI,
28%–41%), and for those vaccinated with RTS,S/AS01 to be
48% (95% CI, 40%–57%). Although, overall, RTS,S/AS01 is
more efficacious than RTS,S/AS02, there is a substantial variation
in efficacy among vaccinated volunteers. Figure 4 shows the
estimated distribution of efficacy against infection for both RTS,S/
AS02 and RTS,S/AS01. The distribution of efficacy is consistent
with RTS,S being a leaky vaccine, but with substantial variation in
efficacy [37,38].
A comparison of efficacy against infection as a function of anti-
CSP antibody titres is shown in Figure 5 for RTS,S/AS01 and
RTS,S/AS02. There was no significant difference in the
relationship between anti-CSP titres and efficacy against infection,
indicating that adjuvant formulation does not alter the quality of
the induced immune responses, but contributes to protection only
by increasing the magnitude of induced immune responses. This is
equivalent to the result that anti-CSP antibody titres but not
adjuvant formulation satisfy the Prentice criterion [39] to be a
surrogate of protection which can be demonstrated using logistic
regression models (see Supplementary Information, Table S8 in
File S1). The Prentice surrogate definition is not suitable for
comparison between vaccinated and control volunteers as there is
not substantial variability in immune responses in the control
volunteers [40], although the data are consistent with anti-CSP
antibodies and numbers of CSP-specific T cells being surrogates of
protection as defined by Qin et al [40].
Discussion
Using an individual level within-host mathematical model of the
processes underlying sporozoite infection, we were able to extend
upon Kester et al’s [29] analysis of aggregated data on immune
responses and time to onset of parasitemia to provide evidence to
support a number of hypotheses for the mechanism of action of the
RTS,S vaccine: (i) anti-CSP antibody titres and CSP-specific
CD4+ T cells constitute surrogates of protection against infection
in the absence of exposure-driven confounding; (ii) when adjusted
for vaccine-induced antibody titres and numbers of CSP-specific
CD4+ T cells, there is no dependence of vaccine efficacy on
adjuvant formulation, i.e. the adjuvant increases the magnitude of
the response but does not change its nature; (iii) RTS,S-induced
immune responses kill greater than 95% of sporozoites suggesting
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that in infected volunteers, the liver-to-blood inoculum may often
be the progeny of a single sporozoite; and (iv) RTS,S is a leaky
vaccine with substantial heterogeneity between individuals in
vaccine efficacy against infection.
Our model results predict that RTS,S-induced protection from
infection is dependent on both anti-CSP antibodies and CSP-
specific CD4+ T cells, with antibodies playing a dominant role in
preventing infection. However, this finding is based on the number
of CSP-specific CD4+ T cells per million expressing $2 of the
cytokines IL-2, TNF-a, IFN-c or the co-stimulatory molecule
CD40L as a marker of cellular immunity [29]. We did not find any
other combination of these parameters to be more predictive, in
contrast to other studies suggesting that CSP-specific CD4+ T cells
producing TNF-a have been associated with a reduced risk of
clinical malaria in a trial of RTS,S/AS01 in children [25]. Other
sub-populations of T cells may be more strongly associated with
vaccine efficacy with Lumsden et al observing an association
between IL-2 and TNF-a producing effector and central memory
CD4+ T cells and protection [41]. A possible hypothesis for the
higher level of protection conferred by antibodies than cellular
responses is the random nature in which a T cell encounters an
infected hepatocyte. Furthermore, RTS,S-induced T cell respons-
es are relatively low compared with classic T cell inducing vaccines
such as BCG, whereas the antibody response is high compared to
most other vaccines.
RTS,S has been observed to be more immunogenic when
formulated with AS01 compared to when formulated with AS02
[13]. This was demonstrated in the original study reporting these
data which summarized a range of immune markers in the two
groups. In endemic settings, RTS,S/AS02 has been observed to
have 30% (95% CI, 11%–45%) efficacy against first episodes of
clinical malaria in Mozambican children [7], compared to
RTS,S/AS01 which was observed to have 53% (95% CI, 28%–
69%) efficacy against first episodes in Kenyan and Tanzanian
children [8]. Our results demonstrate that the differences in
observed efficacy for these two formulations of RTS,S can be
explained by the induction of higher anti-CSP antibody titres and
greater numbers of CSP-specific CD4+ T cells by RTS,S/AS01
compared to RTS,S/AS02.
Our results indicate that RTS,S prevents the majority of P.
falciparum parasites from surviving the pre-erythrocytic stage of
infection, with an estimated efficacy per sporozoite of 96.1% (95%
CI, 93.4%–97.8%). A comparably high level of efficacy per
sporozoite for pre-erythrocytic vaccines has been suggested by the
results of longitudinal PCR studies on challenged volunteers
[20,36]. Such high levels of efficacy per sporozoite are needed to
obtain significant rates of sterile protection for individual
volunteers, given that a single sporozoite evading the vaccine-
induced immune response can lead to blood-stage infection. The
need for such high levels of efficacy per sporozoite to result in even
Figure 5. Comparison of efficacy against infection for RTS,S/AS01 and RTS,S/AS02. Comparison of efficacy against infection as a function
of anti-CSP antibody titre in the absence of CSP-specific CD4+ T cells for RTS,S/AS01 (black) and RTS,S/AS02 (pink) based on the sporozoite infection
model. The grey and pink shaded regions denote 95% confidence intervals for the estimated efficacy of RTS,S/AS01 and RTS,S/AS02, respectively. The
substantial overlap between the two curves indicates that, conditional upon the magnitude of the induced antibody response, RTS,S/AS01 and RTS,S/
AS02 have comparable efficacy. That is, the superior efficacy of RTS,S/AS01 over RTS,S/AS02 is estimated here to be due to the greater magnitude of
the induced immune response and not some other property of the adjuvant.
doi:10.1371/journal.pone.0061395.g005
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a partially effective vaccine is a major challenge in developing
highly efficacious pre-erythrocytic malaria vaccines. No definitive
threshold for protection, in terms of either anti-CSP antibody titres
or CD4+ T cell responses, was identified by our model. Instead,
vaccine efficacy was estimated to increase monotonically, albeit
non-linearly, across the range of observed antibody titres and
cellular responses. With the reduced liver-to-blood inocula (often
the progeny of a single sporozoite) due to vaccination with RTS,S,
there is the possibility that a combination vaccine that also induces
immune responses against blood-stage parasites could eliminate
the few merozoites that do emerge from the liver, although this
was not evident in a study evaluating RTS,S in combination with
MSP-1 [42].
There was significant variation between volunteers in the anti-
CSP antibody titres and numbers of CSP-specific CD4+ T cells on
the day of challenge. Under the sporozoite infection model, this
variation in response predicts substantial between-person hetero-
geneity in vaccine efficacy; that is, partial protection is induced in
everyone but some individuals are more protected than others.
Thus the vaccine is estimated to be leaky but with substantial
variation in efficacy between volunteers. However the findings
presented here only apply on the day of challenge or re-challenge
and do not give information on the duration of protection. The
nature of infectious challenge with malaria may also contribute to
variation in vaccine efficacy as infections arising from bites with a
small number of inoculated sporozoites may be easily prevented,
whereas infections arising from large doses of sporozoites may be
difficult to prevent.
There are a number of limitations to the sporozoite infection
model which describes a simplified version of the processes
underlying P. falciparum infection. Firstly, as a mosquito inoculates
sporozoites into the skin, the probability that one sporozoite
evades the vaccine-induced immune response may not be
independent of the survival of other sporozoites. For example, if
the inoculation site is near a blood vessel then all sporozoites may
evade vaccine-induced immune responses and migrate to the liver
in the blood stream. If the probabilities of sporozoite survival are
not independent, then the efficacy per sporozoite of the vaccine
may be substantially lower than our estimate. Secondly, variation
in both the number of sporozoites and the number of merozoites
per sporozoite will contribute to variation in the liver-to-blood
inocula. For example, high variance in liver-to-blood inocula could
be a result of a constant number of sporozoites releasing a variable
number of merozoites, or a variable number of sporozoites each
releasing a constant number of merozoites. Furthermore, we have
assumed a constant growth rate for blood-stage parasites.
Variation between individuals in this growth rate may additionally
contribute to the variation in time to detection of parasites. The
magnitude of the induced immune responses and the association
between CD4+ T cells and protection from infection may depend
on genetic variation between volunteers, particularly variation in
class II MHC expression which is responsible for priming CD4+ T
cells [43].
Our results suggest that the RTS,S vaccine acts through the
induction of high levels of both anti-CSP antibodies and CSP-
specific CD4+ T cells, with the antibody response having a greater
role. These results can potentially be utilised in endemic settings by
identifying individuals receiving RTS,S who have generated low
vaccine-induced antibody responses and are therefore at greater
risk of re-infection, and who may become a priority for receiving a
booster dose. Identifying covariates such as age, exposure to
malaria and malnutrition that are associated with the magnitude
of vaccine-induced immune responses in children in endemic areas
will aid in the evaluation of the impact of programmes of wide
scale vaccination with RTS,S. Furthermore, the existence of a
subgroup of volunteers with high antibody and cell-mediated
immune responses who display an estimated vaccine efficacy
against infection greater than 70% suggests that substantial
increases in efficacy can be obtained if vaccine immunogenicity
can be further improved.
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